J B Chemicals and Pharmaceuticals Limited has published newspaper advertisements for the notice of equity shareholders meeting convened pursuant to the NCLT tribunal order dated March 23, 2026. The meeting is scheduled to consider and approve the proposed scheme of amalgamation with Torrent Pharmaceuticals Limited.

Shareholder Meeting Details

The company has published advertisements in Indian Express (English Language – All India Editions) and Sandesh (Gujarati Language - Gujarat Edition) on March 28, 2026. The equity shareholders meeting will be conducted through video conferencing or other audio visual means in compliance with applicable regulations.

E-Voting Schedule

The company has arranged remote e-voting facility for equity shareholders prior to the meeting. Physical attendance at the meeting has been dispensed with, and shareholders can participate through the digital platform.

NCLT Order Updates

The tribunal issued a corrigendum order on March 24, 2026, which was uploaded on the NCLT's official website on March 25, 2026. This follows the company's earlier intimation regarding the original order passed by the NCLT Ahmedabad Bench in connection with the proposed amalgamation.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Vice President – Secretarial Sandeep Phadnis signed the regulatory filing on March 28, 2026, informing BSE Limited about the newspaper advertisement publication.

Under the proposed scheme of amalgamation, J.B. Chemicals & Pharmaceuticals Limited will serve as the transferor company, while Torrent Pharmaceuticals Limited will act as the transferee company. The meeting notice and scheme documents are available on the company's website and stock exchange platforms for shareholder access.

J.B. Chemicals & Pharmaceuticals Limited successfully completed its postal ballot process on March 24, 2026, with shareholders overwhelmingly approving all five proposed director appointments. The pharmaceutical company announced the results following a comprehensive e-voting process that demonstrated strong shareholder support for the new leadership structure.

Postal Ballot Process and Participation

The postal ballot was conducted pursuant to a notice dated January 21, 2026, in accordance with Section 110 of the Companies Act, 2013. The e-voting period remained open from February 22, 2026, at 9:00 a.m. to March 23, 2026, at 5:00 p.m., facilitated through the National Securities Depository Limited (NSDL) portal.

Director Appointment Results

All five ordinary resolutions received substantial shareholder approval, with participation representing 80.99% of the company's total paid-up equity capital of 160,527,546 shares.

Key Appointments Approved

Aman Mehta - Dual Role Appointment The shareholders approved two separate resolutions for Mr. Aman Mehta (DIN: 08174906):

Non-Executive Non-Independent Directors Three additional directors were appointed to strengthen the board:

Director Profiles and Expertise

Aman Mehta - Managing Director Mr. Aman Mehta brings extensive pharmaceutical industry experience as the current Managing Director of Torrent Pharmaceuticals Limited. With a Bachelor's degree in Economics from Boston University and MBA from Columbia University, he has over a decade of experience within the Torrent Group. His appointment as Managing Director is effective for a period of 3 years from January 21, 2026.

Amal Kelshikar - Non-Executive Director Mr. Amal Kelshikar contributes 32 years of experience in strategic planning, marketing, and business development. He holds a BE (Chemical) from University Department of Chemical Technology, Mumbai, and MBA from Indian Institute of Management, Ahmedabad. He has been overseeing India business of Torrent Pharmaceuticals Limited since 2022.

Hasmukh Patel - Non-Executive Director Mr. Hasmukh Patel brings over 33 years of pharmaceutical industry experience, currently serving as Chief Operating Officer at Torrent Pharmaceuticals Limited. He holds a master's degree in pharmacy and has been with Torrent since May 1992, rising from Trainee Scientist to his current leadership role.

Sudhir Menon - Non-Executive Director Mr. Sudhir Menon is a Chartered Accountant and Cost Accountant with over 29 years of experience in finance and corporate management. He currently serves as Executive Director (Finance) & Chief Financial Officer of Torrent Pharmaceuticals Limited, joining the company in May 2006.

Voting Pattern Analysis

The voting results demonstrated strong consensus across all shareholder categories. The Promoter and Promoter Group, holding 78,357,892 shares, voted 100% in favor of all resolutions. Public institutional investors, representing 59,356,787 shares, showed participation rates of 84.44% with approval rates exceeding 98% across all resolutions.

Public non-institutional shareholders, despite lower participation at 6.74%, maintained consistent support with approval rates above 98% for all appointments. The minimal dissent across categories reflects confidence in the proposed leadership structure.

Regulatory Compliance and Documentation

The postal ballot process was conducted under the supervision of Mr. Ashish Bhatt of Ashish Bhatt & Associates, who served as the appointed scrutinizer. The scrutinizer's report, dated March 24, 2026, confirmed the validity of all votes and the proper conduct of the e-voting process. The results were declared in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency and regulatory adherence throughout the process.